Development

The company is launching a new pre-fabricated, ready-to-run manufacturing facility that is expected to significantly decrease the production timeline for viral vector-based therapeutics.

Kemiex trading network is designed to increase safety in the sourcing of APIs and additives.

Roche has acquired a program to develop regenerative therapies for multiple sclerosis.

Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.

National Institutes of Health researchers use genomics to show that squamous cell carcinomas differ from other cancers, which could advance treatments for head and neck and other cancers.

Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.

On Tuesday, April 24, 2018, Evan Boswell, senior principal scientist at Pfizer CentreOne Contract Manufacturing, Pfizer CentreOne will give a presentation on scaling up the manufacturing process of active pharmaceutical ingredients at CPhI North America in Philadelphia, PA.

The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.

Access to multiple analytical techniques is essential for fully characterizing complex protein formulations.

This is the first of a series of three articles about validation and technical transfer in the bio- pharmaceutical industry.

Advances in wearable devices have made it possible to deliver high-volume, high-viscosity biologics.

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Gyros Protein Technologies’ new immunoassay technology includes expanded software to optimize time to results and sample capacity while simplifying workflows.

The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.

The company plans to install 4000-L disposable bioreactors from ABEC at its new commercial manufacturing facility in Wuxi city, China.

Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.

Sartorius Stedim Biotech has launched a new automated parallel bioreactor system for perfusion culture.

Sensors and devices being developed by nGageIT Digital Health Solutions can track patient use of oral solid-dosage or injectable drugs.

Process validation is an extension of biologics development processes.

Successful outsourcing relationships for early phase analytics in drug development are driven by partnership.

Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.

GlobalData reports the need to shift away from egg-based manufacturing of vaccines in light of influenza-related deaths.

Modeling at various stages of the data analytics continuum aids scale comparison of a bioreactor.

PharmaMar has released the results of MI130004, a novel antibody drug conjucate created using a molecule of marine origin.

Avid Bioservices will provide commercial manufacture of an enzyme replacement therapy by Roivant Sciences' Enzyvant subsidiary.

The research partnership will focus on advancing regenerative medicine using porcine bioproducts.

The study suggests that circumventing evolution in cell factories can enable the commercialization of new biobased chemicals to large-scale.

Researchers at the University of Illinois developed a method to transplant pancreatic islet cells from pigs more easily to treat type I diabetes.

Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.

A new report states that more research and clinical development must be done in the treatment of pain and addiction.